Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: A pooled analysis of the EINSTEIN-DVT and PE randomized studies

被引：384

作者：

Prins M.H. ^{[1
]}

Lensing A.W.A. ^{[2
]}

Bauersachs R. ^{[3
]}

van Bellen B. ^{[4
]}

Bounameaux H. ^{[5
]}

Brighton T.A. ^{[6
]}

Cohen A.T. ^{[7
]}

Davidson B.L. ^{[8
]}

Decousus H. ^{[9
]}

Raskob G.E. ^{[10
]}

Berkowitz S.D. ^{[11
]}

Wells P.S. ^{[12
]}

机构：

[1] Maastricht University Medical Center, Maastricht

[2] Bayer HealthCare AG, Wuppertal

[3] Klinikum Darmstadt, Darmstadt

[4] Hospital Beneficência Portuguesa, São Paulo

[5] Department of Medicine, University Hospitals of Geneva, Faculty of Medicine, Geneva

[6] Department of Haematology, Prince of Wales Hospital, Sydney, NSW

[7] Department of Haematological Medicine, King's College Hospital, London

[8] University of Washington School of Medicine, Seattle, WA

[9] Service de Médecine et Thérapeutique, CHU Saint-Etienne, Saint-Etienne

[10] University of Oklahoma Health Sciences Center, College of Public Health, Oklahoma City, OK

[11] Bayer HealthCare Pharmaceuticals, Whippany, NJ

[12] Department of Medicine, University of Ottawa and the Ottawa Hospital Research Institute, Ontario

来源：

Thrombosis Journal | / 11卷 / 1期

关键词：

Randomized controlled trials; Rivaroxaban; Standard therapy; Venous thromboembolism;

D O I：

10.1186/1477-9560-11-21

中图分类号：

学科分类号：

摘要：

Background: Standard treatment for venous thromboembolism (VTE) consists of a heparin combined with vitamin K antagonists. Direct oral anticoagulants have been investigated for acute and extended treatment of symptomatic VTE; their use could avoid parenteral treatment and/or laboratory monitoring of anticoagulant effects.Methods: A prespecified pooled analysis of the EINSTEIN-DVT and EINSTEIN-PE studies compared the efficacy and safety of rivaroxaban (15 mg twice-daily for 21 days, followed by 20 mg once-daily) with standard-therapy (enoxaparin 1.0 mg/kg twice-daily and warfarin or acenocoumarol). Patients were treated for 3, 6, or 12 months and followed for suspected recurrent VTE and bleeding. The prespecified noninferiority margin was 1.75.Results: A total of 8282 patients were enrolled; 4151 received rivaroxaban and 4131 received standard-therapy. The primary efficacy outcome occurred in 86 (2.1%) rivaroxaban-treated patients compared with 95 (2.3%) standard-therapy-treated patients (hazard ratio, 0.89; 95% confidence interval [CI], 0.66-1.19; pnoninferiority < 0.001). Major bleeding was observed in 40 (1.0%) and 72 (1.7%) patients in the rivaroxaban and standard-therapy groups, respectively (hazard ratio, 0.54; 95% CI, 0.37-0.79; p = 0.002). In key subgroups, including fragile patients, cancer patients, patients presenting with large clots, and those with a history of recurrent VTE, the efficacy and safety of rivaroxaban were similar compared with standard-therapy.Conclusion: The single-drug approach with rivaroxaban resulted in similar efficacy to standard-therapy and was associated with a significantly lower rate of major bleeding. Efficacy and safety results were consistent among key patient subgroups.Trial registration: EINSTEIN-PE: ClinicalTrials.gov, NCT00439777; EINSTEIN-DVT: ClinicalTrials.gov, NCT00440193. © 2013 Prins et al.; licensee BioMed Central Ltd.

引用

共 19 条

[11]

Hutten B.A., Lensing A.W., Kraaijenhagen R.A., Prins M.H., Safety of treatment with oral anticoagulants in the elderly. A systematic review, Drugs Aging, 14, pp. 303-312, (1999)

[12]

Bauersachs R., Lensing A.W.A., Pap A., Decousus H., No need for a rivaroxaban dose reduction in renally impaired patients with symptomatic venous thromboembolism [abstract], J Thromb Haemost, 11, pp. 30-31, (2013)

[13]

Prandoni P., Lensing A.W.A., Piccioli A., Bernardi E., Simioni P., Girolami B., Marchiori A., Sabbion P., Prins M.H., Noventa F., Girolami A., Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis, Blood, 100, pp. 3484-3488, (2002)

[14]

Prins M.H., Lensing A.W.A., Derivation of the non-inferiority margin for the evaluation of direct oral anticoagulants in the treatment of venous thromboembolism, Thromb J, 11, (2013)

[15]

Gail M., Simon R., Testing for qualitative interactions between treatment effects and patient subsets, Biometrics, 41, pp. 361-372, (1985)

[16]

Buller H.R., Cohen A.T., Davidson B., Decousus H., Gallus A.S., Gent M., Pillion G., Piovella F., Prins M.H., Raskob G.E., Idraparinux versus standard therapy for venous thromboembolic disease, N Engl J Med, 357, pp. 1094-1104, (2007)

[17]

Zondag W., Mos I.C., Creemers-Schild D., Hoogerbrugge A.D., Dekkers O.M., Dolsma J., Eijsvogel M., Faber L.M., Hofstee H.M., Hovens M.M., Jonkers G.J., Van Kralingen K.W., Kruip M.J., Vlasveld T., De Vreede M.J., Huisman M.V., Outpatient treatment in patients with acute pulmonary embolism: the Hestia Study, J Thromb Haemost, 9, pp. 1500-1507, (2011)

[18]

Erkens P.M., Ten Cate H., Buller H.R., Prins M.H., Benchmark for time in therapeutic range in venous thromboembolism: a systematic review and meta-analysis, PLoS One, 7, (2012)

[19]

Kearon C., Akl E.A., Comerota A.J., Prandoni P., Bounameaux H., Goldhaber S.Z., Nelson M.E., Wells P.S., Gould M.K., Dentali F., Crowther M., Kahn S.R., Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines, Chest, 141, (2012)

← 1 2 →